EC0652 moving to phase 2 before the end of the year.
Merk initiating the 3 other indications 1Q 2013
Tubulysin is moving to clinical in 2Q 2013
Inflammation moving to clinical 3Q - 4Q 2013
Approval of Ovarian Europe application 4Q 2013 -1 Q 2014
Data for Phase 3 proceed 1Q 2014 and submittable in USA
Data for NSLC 1Q-2Q 2014 and submittable in USA
PKD will have clear vision in 2013
CASH of 204million + milestone payment and Merk is paying the bill for development cost.
IMO it is a heavenly investment !!!!
please feel free to add or comment on my little summery